Lv11
70 积分 2025-03-19 加入
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas
3个月前
已完结
Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway
3个月前
已完结
Clonotype-Immunophenotype Relationships in TET2 and IDH-Mutant Myeloid Transformation
4个月前
已关闭
Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph
4个月前
已关闭
Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction
4个月前
已完结
Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression
4个月前
已完结
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies
4个月前
已完结
Identification of the Highly Active, Species Cross-Reactive Complex I Inhibitor BAY-179
4个月前
已完结
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
4个月前
已完结
The implications of IDH mutations for cancer development and therapy
5个月前
已完结
皖公网安备34019202002308
